Kunz Stefanie, Dolch Anja, Surianarayanan Sangeetha, Dorn Britta, Bewersdorff Mayte, Alessandrini Francesca, Behrendt Rayk, Karp Christopher L, Muller Werner, Martin Stefan F, Roers Axel, Jakob Thilo
Allergy Research Group, Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.
Eur J Immunol. 2016 Aug;46(8):2018-27. doi: 10.1002/eji.201646319. Epub 2016 Jul 11.
Regulatory mechanisms initiated by allergen-specific immunotherapy are mainly attributed to T cell derived IL-10. However, it has not been shown that T cell derived IL-10 is required for successful tolerance induction (TI). Here, we analyze cellular sources and the functional relevance of cell type specific IL-10 during TI in a murine model of allergic airway inflammation. While TI was effective in IL-10 competent mice, neutralizing IL-10 prior to tolerogenic treatment completely abrogated the beneficial effects. Cellular sources of IL-10 during TI were identified by using transcriptional reporter mice as T cells, B cells, and to a lesser extent DCs. Interestingly, TI was still effective in mice with T cell, B cell, B and T cell, or DC-specific IL-10 deficiency. In contrast, TI was not possible in mice lacking IL-10 in all hematopoetic cells, while it was effective in bone marrow (BM) chimera that lacked IL-10 only in nonhematopoetic cells. Taken together, allergen-specific tolerance depends on IL-10 from hematopoetic sources. The beneficial effects of allergen-specific immunotherapy cannot solely be attributed to IL-10 from T cells, B cells, or even DCs, suggesting a high degree of cellular redundancy in IL-10-mediated tolerance.
由变应原特异性免疫疗法启动的调节机制主要归因于T细胞衍生的白细胞介素-10(IL-10)。然而,尚未证明T细胞衍生的IL-10是成功诱导耐受(TI)所必需的。在此,我们在变应性气道炎症的小鼠模型中分析了TI期间细胞来源以及细胞类型特异性IL-10的功能相关性。虽然TI在具有IL-10能力的小鼠中有效,但在进行致耐受性治疗之前中和IL-10完全消除了有益效果。通过使用转录报告基因小鼠确定TI期间IL-10的细胞来源为T细胞、B细胞,以及程度较轻的树突状细胞(DC)。有趣的是,TI在T细胞、B细胞、B和T细胞或DC特异性IL-10缺陷的小鼠中仍然有效。相比之下,在所有造血细胞中缺乏IL-10的小鼠中无法进行TI,而在仅非造血细胞中缺乏IL-10的骨髓(BM)嵌合体中TI是有效的。综上所述,变应原特异性耐受取决于造血来源的IL-10。变应原特异性免疫疗法的有益效果不能仅仅归因于来自T细胞、B细胞甚至DC的IL-10,这表明在IL-10介导的耐受中存在高度的细胞冗余。